Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Crucell  /  Sectornieuws - Biotech en Pharma

Ontvang nu dagelijks onze kooptips!

word abonnee

Crucell« Terug naar discussie overzicht

Sectornieuws - Biotech en Pharma

690 Posts
Pagina: «« 1 ... 4 5 6 7 8 ... 35 »» | Laatste | Omlaag ↓
  1. [verwijderd] 25 maart 2009 12:32
    Roche Says RiskMetrics Backs Genentech Takeover At $95/Share

    Last update: 3/24/2009 1:38:32 PM

    ZURICH (Dow Jones)--Roche Holding AG (RHHBY) said Tuesday RiskMetrics recommends Genentech Inc. (DNA) shareholders accept the Swiss drug company's $95-a-share takeover offer.

    The $46.8 billion purchase for the 44% of Genentech Inc. (DNA) Roche doesn't already own was ultimately reached through a friendly deal two weeks ago after a nearly eight-month battle. RiskMetrics provides proxy voting recommendations and other shareholder services.

    Company Web site: www.roche.com

    -By Katharina Bart, Dow Jones Newswires; +41 43 443 8043; katharina.bart@dowjones.com (END) Dow Jones NewswiresMarch 24, 2009 13:38 ET (17:38 GMT)
  2. [verwijderd] 25 maart 2009 12:50
    Nou, Novartis valt ook al af als kandidaad-koper voor Cru.

    [:>)

    PRESS RELEASE: Novartis Makes An Open Offer To Increase Stake In Novartis India Ltd.
    Last update: 3/24/2009 9:02:56 PM

    = -

    Corporate news announcement processed and transmitted by Hugin AS.
    The issuer is solely responsible for the content of this

    This release is neither an offer to purchase nor a solicitation of an
    offer to sell shares of Novartis India Ltd.

    Basel, Switzerland, March 25, 2009 - Novartis announced today a
    tender offer to acquire an additional stake of up to approximately
    39% in its majority-owned Indian subsidiary, Novartis India Ltd.,
    from public shareholders at a price of Rs 351 per share.

    Successful completion of this offer (assuming full acceptance) would
    raise the stake of Novartis in its Indian subsidiary to nearly 90%
    from the current level of 50.9%. The offer represents a total value
    of up to Rs 4.4 billion (or approximately USD 87 million).

    A public announcement is being published in India as required by law.
    The offer for these shares, which are traded on the Bombay Stock
    Exchange, is expected to open in May 2009 and is subject to
    regulatory approvals.

    The offer by Novartis AG, a Group subsidiary, has been made at a
    premium of 27% to the closing share price of Rs 275.6 of Novartis
    India Ltd. on March 24, which was the last trading day before this
    announcement. It also represents a premium of 35% over Novartis India
    Ltd.'s average share price during the last month.
  6. [verwijderd] 26 maart 2009 21:26
    EMERFLU®, pandemic influenza vaccine for humans, approved in Australia

    Lyon, France – March 26, 2009 - Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that its pandemic influenza vaccine for human use Emerflu®*, has been granted marketing authorization from the Australian Therapeutic Goods Administration (TGA). Emerflu® vaccine is now approved for the prevention of pandemic influenza in Australia upon official declaration of a pandemic. Emerflu® vaccine is intended to be manufactured and distributed with the identified pandemic strain and used in Australia in accordance with official Australian government guidance.

    The Australian approval of Emerflu® vaccine granted today follows the positive recommendation by the Australian Drug Evaluation Committee (ADEC) on February 13 2009, based on a review of results from clinical trials, which began in late 2004 on H5N1 alum-adjuvanted** inactivated influenza vaccine candidates. These trials evaluated the safety and ability of Emerflu® vaccine to elicit a protective immune response to the H5N1 strains currently identified by global health authorities and experts as a potential source for the next pandemic.

    “The Australian TGA’s recommendation of Emerflu® vaccine marks a new milestone in pandemic preparedness,” said Wayne Pisano, President and CEO of sanofi pasteur. According to the World Health Organization (WHO), influenza vaccines are considered to be the most important and potentially effective intervention for mitigating the effects of an influenza pandemic1. The optimal choice of strain and formulation for an effective vaccine will be possible when the pandemic influenza strain has emerged1,2. “As the world’s leading influenza vaccine manufacturer, sanofi pasteur aims at contributing to the efforts of WHO, Australia and other countries around the world to safeguard human health in the event of an influenza pandemic,” added Pisano.

    Sanofi pasteur is actively involved in pandemic preparedness and has invested in a major expansion of its influenza vaccine production capacity in the U.S., France, China and Mexico. Sanofi Pasteur is also committed to continuing its robust research and development program by exploring strategies for protecting more people. This includes the evaluation of new vaccine formulations to generate immune responses against other strains of the H5N1 virus as well as the use of adjuvants or immunostimulators*** to increase the response to the vaccine.

    en.sanofi-aventis.com/binaries/2009-0...
  7. [verwijderd] 27 maart 2009 20:07
    Is Biogen Idec setting itself up to be acquired?
    March 26, 2009

    in Biogen Idec

    It’s certainly no secret that Biogen has been considered a potentially attractive acquisition target for some time. The company actively sought an acquirer in 2007, but decided to remain an independent entity when there appeared to be a significant discrepancy between the asking price and the price that potential acquirers were willing to pay. Much of this discrepancy was attributed to uncertainty over future Tysabri sales. Tysabri had been re-introduced to the market during the previous year and the industry seemed intent on watching to see if the number of PML cases associated with the use of the drug would be something that the company could live with or de-risk.

    The past few days have seen Biogen make a number of announcements that clearly signal their intent to mitigate this risk while highlighting the strength of their late-stage pipeline. The company announced that it is exploring the use of Roche’s anti-malarial drug mefloquine for the treatment of PML and that its JC virus test may be available by the end of 2009. If the work pans out, these tools could allow clinicians to identify patients who might be at greater risk for developing PML, monitor them more closely, and potentially treat them at the first signs of the disease. Although the risk of developing PML is extremely low, some analysts estimate that the sales of the drug could triple if the PML risk is addressed. Tysabri sales in 2008 were $813M.

    Cecil Pickett, President of R&D at Biogen, gave a presentation yesterday that highlighted the overall strength of Biogen’s pipeline, particularly its late-stage programs. You can view the presentation here, but perhaps the most telling slide is the one reproduced below (click to enlarge). The slide shows a ranking of late-stage pipeline quality by Moody’s. Of the top seven companies, three (Schering-Plough, Genentech and Wyeth) have been acquired within the past few weeks and Allergan is rumored to be in talks to be acquired by GlaxoSmithKline. With J&J’s pharmaceutical business not for sale and Amgen being a much more expensive and less malleable target, that leaves one of the top seven standing standing.

    realbiotek.com/antibodyblog/2009/03/2...
    Bijlage:
  8. [verwijderd] 27 maart 2009 20:17
    Pharmacy News Article
    3/20/09 - Confirmation of Bogoch Replikins Influenza Patents by Harvard-CDC and Scripps-Crucell Data

    BOSTON, March 20 /PRNewswire/ -- Replikins, Ltd. announced today that data recently published from Harvard-CDC and Scripps-Crucell in Nature(1) and Science(2) confirms the 2001 discoveries by Dr. Samuel and Elenore Bogoch of peptides in the hemagglutinin unit of influenza, which they named Replikins, which are shared across flu strains, conserved over time, associated with the last three pandemics of 1918, 1957 and 1968, as well as current H5N1 outbreaks, and are the basis of broad spectrum flu vaccines. The Replikins sequences, as specified by the Bogoches, are the subject of granted patents from 2001 and a 2005 monograph(3).

    The amino acid contact points between the neutralizing antibody and the virus that the Harvard-CDC and Scripps-Crucell investigators both observed, out of over 500 possible sites, are in the influenza Replikins. The confirming groups' data also verified the Bogoch 2001 findings of conservation of these very Replikins peptides over decades, and the sharing of Replikins between strains of influenza, making general flu vaccines possible for the first time.

    The Replikins peptides, associated with rapid replication, are quantitatively trackable and predictive of the intensity, timing, and country of outbreak. The company's FluForecast(R) software has correctly predicted recent H5N1 outbreaks and the countries in which they were going to occur(4).

    Replikins, which are quantitatively related to lethality in influenza and other infectious diseases, such as HIV, anthrax, and malaria, as well as cancer, and a range of animal diseases, are the subject of synthetic vaccines in development at the Company.


    www.pharmacychoice.com/News/article.c...

  9. [verwijderd] 31 maart 2009 15:10

    blogs.wsj.com/health/2009/03/30/lilly...
    * March 30, 2009, 9:26 AM ET

    By Sarah Rubenstein

    Eli Lilly is resisting getting caught up in the wave of drug-industry consolidation.

    After Pfizer-Wyeth, Merck/Schering-Plough and Roche-Genentech, Lilly CEO John Lechleiter told the Financial Times his company isn’t interested in a mega-merger, and he ruled out a tie-up with Bristol-Myers Squibb.

    “I think we are seeing deals that are really driven more by weakness than what I would describe as strong strategic combinations,” Lechleiter told the FT. “That will improve short-term problems but fail to answer the long-term question of research productivity.”

    As the WSJ explained a few weeks ago, Lilly is looking relatively small in the wake of the mega mergers, and it’s facing the loss of patent protection of the big-selling antipsychotic Zyprexa in 2011. Lilly would more likely be a buyer than a seller. Still, a spokesman told the WSJ that the company isn’t interested in large-scale M&A and believes that “small and medium scale acquisitions, licensing and internal development” are the best way forward for Lilly.

    “Call me a stubborn Midwesterner, but I/we continue to believe that these megadeals never made any sense to begin with and don’t make sense now,” Lechleiter wrote in an in-house blog post, as quoted by the FT. “We are flat out not interested in being part of a big combination.”

    Update: Lechleiter tells the WSJ he is interested in acquisitions of up to about $15 billion. “I got hungry again about three weeks after ImClone got closed,” he said.

    Dirk
  13. [verwijderd] 5 april 2009 09:18
    MARCH 31, 2009 Eli Lilly Is on Hunt for Acquisitions

    By JONATHAN D. ROCKOFF
    INDIANAPOLIS -- Eli Lilly & Co. Chief Executive John Lechleiter said the drug maker is looking for acquisitions of as much as $15 billion now that it has digested ImClone Systems.

    "I got hungry again about three weeks after ImClone got closed" in late November, Dr. Lechleiter said in an interview.

    Major drug makers are snapping up large rivals after failing to develop lucrative new drugs to replace their aging blockbusters. Analysts estimate that drugs with $30 billion in sales will go off patent and face competition from cheaper generics in the next several years.


    John Lechleiter
    Pharmaceutical companies are also trying to expand beyond prescription drugs after concluding that drug discovery is too unpredictable to provide stable growth. The recession is spurring them to maximize cash flow and diversify their sources of revenue.

    In January, Pfizer Inc. agreed to take over Wyeth for $68 billion, a deal that enabled it to expand into biotech drugs, consumer health and animal health products. That takeover was followed by a merger between Merck & Co. and Schering-Plough Corp., and Roche Holding AG's successful bid to buy the rest of Genentech Inc. it didn't own.

    Even Abbott Laboratories Inc., a company that already was diversified, appears to be on the takeover trail. Abbott was the mysterious "Company X" that Pfizer reported in securities filings last week had approached Wyeth in December about a potential counterbid, said people familiar with the matter. Abbott couldn't be reached for comment.

    Dr. Lechleiter said in the interview he wants to diversify Indianapolis-based Lilly's product lineup to offset revenue declines some of the company's drugs will face in the next several years from competition with cheaper generics. Lilly's best-selling drug, the antipsychotic Zyprexa, loses patent protection in 2011.

    Dr. Lechleiter ruled out a mega merger like the Pfizer or Merck deals, saying it's not clear major drug-industry mergers are an advantage. "There's no evidence that a consolidated industry is a more productive industry," Dr. Lechleiter said. "I don't think any of these large-scale consolidations address innovation."

    Pfizer, Merck and Roche declined to comment on Dr. Lechleiter's view.

    Losing patent protection on Zyprexa will be a big blow for Lilly. The drug accounted for about a fifth of the company's $20.38 billion in world-wide sales last year. And its second- and third-leading selling drugs, with a combined $4.43 billion in sales last year, are set to face generic competition in 2013.

    While rivals grow significantly larger through acquisitions, Dr. Lechleiter said Lilly was comfortable looking small by comparison and preferred to grow incrementally. Dr. Lechleiter said Lilly would pursue acquisitions costing from $5 billion to $15 billion. The company wants to expand its animal-health business and was also scouring the cash-strapped biotechnology industry for good values, he said.

    "We're going to look for opportunities to be a bit more diverse pharmaceutical company. We're not going to buy a medical-device company. We're not going to buy a diagnostic company," he said.

    He said Lilly wants to make more deals like its $6.5 billion takeover of ImClone, which added biotech cancer therapies already on the market and in development to Lilly's oncology line-up. He did not say which companies he is looking at.

    Executives at Lilly believe the industry needs to increase the number of drugs in development to overcome the historically low odds of finding a new blockbuster. They see acquisitions as a means to expand Lilly's pipeline.

    Toward that same end, Lilly also has been acting as a kind of Asian venture capitalist, making $50 million in investments in promising start-ups, including three in China. "We're planting a garden," Dr. Lechleiter said.

    —Matthew Karnitschnig contributed to this article.

    online.wsj.com/article/SB123843024162...
  14. [verwijderd] 7 april 2009 14:04
    Multinationals Interested In Wockhardt Health Ops - Report

    Last update: 4/6/2009 6:53:10 PM

    DOW JONES NEWSWIRES

    Pfizer Inc. (PFE) and Sanofi-Aventis (SNY) are among the multinational pharmaceutical companies involved in due diligence of Wockhardt Ltd.'s (532300.BY) animal healthcare business, the Economic Times reported on its Web site Tuesday, citing people close to the development.

    Wockhardt and Sanofi-Aventis declined to comment, while Pfizer didn't reply to an email, the Web site said. Wockhardt plans to raise around INR1.5 billion ($29.9 million) from the sale of its animal healthcare business, the Web site reported.
    Full story: economictimes.indiatimes.com/News-by-... (END) Dow Jones NewswiresApril 06, 2009 18:53 ET (22:53 GMT)
  15. [verwijderd] 8 april 2009 13:55
    J&J: Co Doesn't Have Plans To Enter 'Biosimilars' Market
    Last update: 4/7/2009 1:01:19 PM

    By Jared A. Favole
    Of DOW JONES NEWSWIRES
    WASHINGTON (Dow Jones)--A Johnson & Johnson (JNJ) policy director on Tuesday said the health-care conglomerate doesn't have plans to get into the "biosimilars" market, but didn't rule out doing so in the future.

    The New Jersey-based company has had success with biologics, complex and expensive medicines derived from living organisms. But it doesn't currently have plans to enter the market for biosimilars, which are cheaper, generic-like versions of biologics, said Audrey Phillips, an executive director of public policy for J&J. J&J's moves differ from those of other pharmaceutical companies.

    Merck & Co. (MRK) has created a new division to launch biosimilars, and Eli Lilly & Co. (LLY) has said it would consider entering that market. Several bills in Congress would make it easier for biosimilars to make it to market, though the bills differ widely.

    A bill proposed by Reps. Joe Barton, R.-Texas, and Anna Eshoo, D.-Calif, gives brand-name biologic makers 12 years of exclusivity before generic versions can hit the market. Rep. Henry Waxman, D.-Calif., introduced a bill that would give brand-name biologics only five years of exclusivity before generic versions could reach the market.

    The exclusivity in the Waxman bill is "far from sufficient," Phillips said, echoing sentiments by economists and others in the pharmaceutical industry that companies need about 12 years of exclusivity to have the financial incentive to make medical products.

    Making such products can be costly and take decades to develop. Phillips added that JNJ supports the Barton and Eshoo bill. Phillips and other JNJ officials said biologics are hard to replicate, noting that these medicines are based on more complex molecules than traditional drugs, and they want any legislation to continue to encourage innovation.

    The company highlighted its success with Remicade as a reason why pharmaceutical companies need exclusive time to develop a medical product. The biologic was approved in 1998 to treat a painful inflammatory bowel disease, and has since been expanded to treat rheumatoid arthritis. The biologic brought in sales of $3.7 billion in 2008, making it J&J's largest-selling product.

    Dirk
  18. gogogoo 14 april 2009 14:18
    UPDATE 1-J&J profit beats forecast, shares jump [JNNRXGD]

    * J&J Q1 $1.26/shr vs. forecast of $1.22/shr
    * Reaffirms full-year 2009 forecast
    * Shares rise more than 3 percent

    NEW YORK, April 14 (Reuters) - Johnson & Johnson <JNJ.N> on
    Tuesday said its quarterly earnings fell, hurt by generic
    competition for its Risperdal schizophrenia drug and the strong
    dollar, but lower costs enabled the company to beat Wall Street
    expectations
    The diversified health-care company, whose shares rose more
    than 3 percent in premarket trading, said it earned $3.51
    billion, or $1.26 per share, in the first quarter. That
    compared with $3.6 billion, or $1.26 per share, in the
    year-earlier period.
    Analysts on average expected $1.22 per share, according to
    Reuters Estimates.
    J&J reaffirmed its 2009 profit profit forecast of $4.45 to
    $4.55 per share.
690 Posts
Pagina: «« 1 ... 4 5 6 7 8 ... 35 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 909,81 +0,90%
EUR/USD 1,0875 -0,04%
FTSE 100 8.239,96 +0,10%
Germany40^ 18.515,50 +0,60%
Gold spot 2.332,47 +0,24%
NY-Nasdaq Composite 16.857,05 +0,17%

Stijgers

Xior
+6,04%
Deceun...
+2,85%
AZELIS...
+1,37%
Proximus
+1,08%
DEME G...
+0,87%

Dalers

Ageas
-3,93%
Tessen...
-2,77%
Aperam
-1,89%
Colruyt
-1,88%
Umicore
-1,67%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!